about
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsMicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia.Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Acute human herpesvirus-6A infection of human mesothelial cells modulates HLA molecules.Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders.Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples.Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia.Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance.Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays.Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients.Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosisDasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibAngiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical–biological featuresFour novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma
P50
Q33913537-BCDB985D-1B53-4298-A565-667F08B437CEQ33942272-0C660392-524E-4044-985C-B2F6BC638702Q35001307-02831454-3E67-4633-B13A-CCE1F7E0BA82Q35265868-47522154-F364-43F9-B751-DCDF52566866Q35883836-7B5B857D-7C0B-4716-8EC2-9166C60DED83Q36862301-874FD514-8DC6-4880-BB0C-D1F26CDDB6C7Q38973320-4DAD6D68-9F9A-4264-8C25-7C178BBEE46FQ40821920-1C358C7E-3E0C-426A-9602-62A59CE10AE9Q41153901-5EAA9AED-484C-45A4-897F-E966B37AB6DEQ42822110-F440643D-6A0B-41BA-87BE-CA1036A03733Q43984170-2A0F470C-0569-4D5B-A490-022741839F86Q44117868-BDA7E892-597A-4E76-A6E3-CBEECFC684B8Q44167290-D33F7881-8DF9-4121-987A-F8D231044621Q44220321-D5394870-89A1-487B-9DFC-FB87731EF807Q46913752-0264EB1B-F4E8-410C-A981-2E8BDDE7793FQ49023149-EF8D90D5-C0B9-4866-8D2E-1BA722995EF7Q50784041-0F47DC3B-43DB-4264-81E6-DFC2F7CE0563Q50790201-BBAD75BA-E995-42E3-834C-D7F1E44FCE8FQ50791511-819AC532-3AB7-45EE-934E-DB9E658DE09DQ50801982-C29D9598-5E56-4126-BA06-81C0E3DD64C0Q54573541-66BDCCFF-1E1D-4D52-A4F2-B5682F92693AQ58001012-80139D19-1E81-4B61-A71B-CB675F55835BQ58449042-1420E1B7-803F-4F26-A226-BFD72447AFF5Q60671956-A1097AA8-0B1B-47E5-9E8F-3AB70456685FQ60671959-24935872-5E00-4CC1-A9BF-292CBDE30E0BQ81588531-56B899BE-E090-4DA1-905B-4FBAF9BBA4C7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Cavazzini
@ast
Francesco Cavazzini
@en
Francesco Cavazzini
@es
Francesco Cavazzini
@nl
type
label
Francesco Cavazzini
@ast
Francesco Cavazzini
@en
Francesco Cavazzini
@es
Francesco Cavazzini
@nl
prefLabel
Francesco Cavazzini
@ast
Francesco Cavazzini
@en
Francesco Cavazzini
@es
Francesco Cavazzini
@nl
P106
P1153
35405339400
P21
P31
P496
0000-0002-8290-1253